Clinical Policy: Pralsetinib (Gavreto)
Reference Number: ERX.SPA.414
Effective Date: 12.01.20
Last Review Date: 11.20
Line of Business: Commercial, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Pralsetinib (Gavreto™) is an oral tyrosine kinase inhibitor of wild-type rearranged during transfection (RET) and oncogenic RET fusions (CCDC6-RET) and mutations (RET V804L, RET V804M, and RET M918T).

FDA Approved Indication(s)
Gavreto is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.*

*This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Gavreto is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Non-Small Cell Lung Cancer (must meet all):
      1. Diagnosis of recurrent, advanced, or metastatic NSCLC;
      2. Prescribed by or in consultation with an oncologist;
      3. Age ≥ 18 years;
      4. Documentation of RET fusion-positive disease (e.g., CCDC6-RET, KIF5B-RET);
      5. Gavreto is not prescribed concurrently with Retevmo™;
      6. Member has not received prior RET targeted therapy (e.g., Retevmo);
      7. Request meets one of the following (a, b, or c):*
         a. Dose does not exceed 400 mg (4 capsules) daily;
         b. Dose does not exceed 800 mg (8 capsules) daily and prescriber attestation of member’s inability to avoid concomitant use of CYP3A inducer (e.g., carbamazepine, rifampin, ritonavir, St. John’s wort);
         c. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

   *Prescribed regimen must be FDA-approved or recommended by NCCN

Approval duration:
Commercial – Length of Benefit
Medicaid – 6 months

B. Other diagnoses/indications
   1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

II. Continued Therapy
   A. Non-Small Cell Lung Cancer (must meet all):
1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions, or documentation supports that member is currently receiving Gavreto for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. Gavreto is not prescribed concurrently with Retevmo;
4. Member has not received prior RET targeted therapy (e.g., Retevmo);
5. If request is for a dose increase, request meets one of the following (a, b, or c):
   a. New dose does not exceed 400 mg (4 capsules) daily;
   b. New dose does not exceed 800 mg (8 capsules) daily and prescriber attestation of member’s inability to avoid concomitant use of CYP3A inducer (e.g., carbamazepine, rifampin, ritonavir, St. John’s wort);
   c. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).
   *Prescribed regimen must be FDA-approved or recommended by NCCN

Approval duration:
Commercial – Length of Benefit
Medicaid – 12 months

B. Other diagnoses/indications (must meet 1 or 2):
1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy.
   Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – ERX.PA.01 or evidence of coverage documents.

IV. Appendices/General Information
Appendix A: Abbreviation/Acronym Key
FDA: Food and Drug Administration
NCCN: National Comprehensive Cancer Network
NSCLC: non-small cell lung cancer
RET: rearranged during transfection

Appendix B: Therapeutic Alternatives
Not applicable

Appendix C: Contraindications/Boxed Warnings
None reported

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSCLC</td>
<td>400 mg PO QD</td>
<td>800 mg/day with coadministration of strong CYP3A inducers</td>
</tr>
</tbody>
</table>

VI. Product Availability
Capsule: 100 mg

VII. References

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy created</td>
<td>10.13.20</td>
<td>11.20</td>
</tr>
</tbody>
</table>

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2020 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.